Visium Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Visium Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-15,300	Closed	-$228K	–	917
2015 Q2	$228K	Buy	+15,300	New	+$174K	﹤0.01%	932
2014 Q1	–	Sell	-234,900	Closed	-$1.78M	–	872
2013 Q4	$1.78M	Sell	234,900 -2,000	-0.8%	-$12.7K	0.04%	363
2013 Q3	$1.73M	Buy	+236,900	New	+$1.2M	0.04%	316

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Visium Asset Management's BCRX Position: Q3 2015 in Review

Visium Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2015, closing a stake of 15,300 shares — an estimated $228K sold.

Visium Asset Management first reported a position in BCRX in Q3 2013 and held it in 3 quarters. The position peaked at $1.78M in Q4 2013. 124 funds tracked by Wall St. Rank hold BCRX as of Q3 2015.

Visium Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Visium Asset Management sold 15,300 BioCryst Pharmaceuticals shares in Q3 2015, an estimated $228K.
Visium Asset Management first reported a position in BioCryst Pharmaceuticals in Q3 2013 and held it in 3 quarters.
Visium Asset Management's BioCryst Pharmaceuticals position peaked at $1.78M in Q4 2013.
124 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2015.

Based on Visium Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.